<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344316</url>
  </required_header>
  <id_info>
    <org_study_id>14-14251</org_study_id>
    <nct_id>NCT02344316</nct_id>
  </id_info>
  <brief_title>Bringing Relief to Adolescents Naturally Using Melatonin for Migraine</brief_title>
  <acronym>BRAiN-M</acronym>
  <official_title>Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: &quot;The BRAiN-M Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy Gelfand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine in adolescents is common and effective and safe preventive treatments are needed.&#xD;
      This is a pilot randomized controlled trial of melatonin versus placebo for migraine&#xD;
      prevention in adolescents 12-17 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot randomized controlled trial of melatonin vs. placebo for migraine prevention&#xD;
      in adolescents 12-17 years old. The main goal of this pilot study is to estimate variance in&#xD;
      the outcome measures to help with planning the future fully powered study. Participants will&#xD;
      have an in person enrollment visit, followed by phone follow up visits and headache diary&#xD;
      data collection via smart phone or internet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Migraine/Migrainous Days Per 28 Day Period</measure>
    <time_frame>final 4 weeks of treatment</time_frame>
    <description>Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Minutes to Sleep Onset</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of minutes to sleep onset as measured by a FitBit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Recruited From Each Recruitment Strategy</measure>
    <time_frame>During the enrollment period, approximately 1 year</time_frame>
    <description>Each recruitment strategy will be analyzed for number of participants successfully enrolled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence as Measured by Number of Openings Per Participant</measure>
    <time_frame>during the &quot;At Home Active Study Period&quot; or Weeks 5-16</time_frame>
    <description>eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Diary Compliance Rate</measure>
    <time_frame>Weeks 12-16 of the study</time_frame>
    <description>Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Migraine in Adolescents</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group randomized to melatonin 3 mg orally nightly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group randomized to placebo orally nightly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Rugby melatonin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 12-17 years and weight ≥40 kg, to allow consistent dosing for all participants of&#xD;
             the melatonin dose that has been found to be effective in adults&#xD;
&#xD;
          2. Resides in California&#xD;
&#xD;
          3. Headache fulfills International Classification for Headache Disorders, Third Edition&#xD;
             (beta version)33 criteria for episodic migraine (with or without aura) in adolescents&#xD;
&#xD;
          4. Has been experiencing episodic headaches for at least six months&#xD;
&#xD;
          5. Experiences between 6-14 days of migraine/migrainous headaches per month at baseline&#xD;
             (cutoff for chronic migraine is ≥15 days/month)&#xD;
&#xD;
          6. Developmentally able to provide age-appropriate level of assent&#xD;
&#xD;
          7. Has a parent/guardian capable of giving written informed consent&#xD;
&#xD;
          8. Has daily access to a smartphone in order to be able to complete daily study&#xD;
             procedures such as diary completion, and to receive text reminders&#xD;
&#xD;
          9. Subject and parent agree the adolescent will not use over-the-counter melatonin, or&#xD;
             another migraine preventive medication, while participating in the study&#xD;
&#xD;
         10. Participant and at least one parent speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently (or within the last 4 weeks) using any medication or device with migraine&#xD;
             preventive properties: i.e. topiramate, amitriptyline, nortriptyline, propranolol,&#xD;
             metoprolol, sodium valproate, gabapentin, flunarizine, methysergide, riboflavin,&#xD;
             butterbur, coenzyme Q10, or the Cefaly TENS device. For onabotulinum toxin, they will&#xD;
             have to have been off it for at least three months&#xD;
&#xD;
          2. Use of other sleep medication or sedating medication, such as benzodiazepines,&#xD;
             trazodone, or melatonin receptor agonists&#xD;
&#xD;
          3. History of allergy or adverse event with previous use of exogenous melatonin&#xD;
&#xD;
          4. Previous ineffective trial of melatonin 3 mg nightly for migraine prevention, where&#xD;
             the trial duration was at least three months in duration&#xD;
&#xD;
          5. Inability to swallow pills, if this inability persists after instruction on&#xD;
             pill-swallowing techniques&#xD;
&#xD;
          6. History of epilepsy or seizure&#xD;
&#xD;
          7. Overuse of acute headache medications, wherein medication overuse is defined33 as ≥4&#xD;
             days per month of barbiturate containing compounds, ≥10 days per month of opioid&#xD;
             containing compounds, or ≥10 days per month of triptans or ergot-containing compounds.&#xD;
             Those using non-specific analgesics ≥15 days per month would also be excluded&#xD;
&#xD;
          8. Adolescent does not have the cognitive capacity to give verbal assent to participate,&#xD;
             or the investigator thinks the adolescent does not have the cognitive capacity to&#xD;
             complete the diary, even with parental assistance&#xD;
&#xD;
          9. For females: Pregnancy, lactating or planning to become pregnant during the study. For&#xD;
             males: planning to father a child during the study&#xD;
&#xD;
         10. Abnormal neurologic examination findings&#xD;
&#xD;
         11. Serious medical illness of any kind; seriousness as judged by the investigator&#xD;
&#xD;
         12. The investigator does not think the participant can comply with study procedures, or&#xD;
             does not think it is medically appropriate for the participant to be in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy A Gelfand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Headache Research and Treatment Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Pediatric Brain Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Masruha MR, Lin J, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF. Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache. 2010 Mar;50(3):413-9. doi: 10.1111/j.1526-4610.2009.01547.x. Epub 2009 Oct 8.</citation>
    <PMID>19817880</PMID>
  </reference>
  <reference>
    <citation>Masruha MR, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008 Aug;9(4):221-4. doi: 10.1007/s10194-008-0047-5. Epub 2008 Jul 2.</citation>
    <PMID>18594760</PMID>
  </reference>
  <reference>
    <citation>Peres MF, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006 Apr;15(4):367-75. Review.</citation>
    <PMID>16548786</PMID>
  </reference>
  <reference>
    <citation>Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757.</citation>
    <PMID>15326268</PMID>
  </reference>
  <reference>
    <citation>Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, Silberstein SD, Zukerman E. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):747-51.</citation>
    <PMID>11723194</PMID>
  </reference>
  <reference>
    <citation>Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015;10(2):132-5.</citation>
    <PMID>24909684</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <results_first_submitted>May 5, 2017</results_first_submitted>
  <results_first_submitted_qc>August 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Amy Gelfand</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was a 28 day baseline run-in prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>Group randomized to melatonin 3 mg orally nightly&#xD;
Melatonin: Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Group randomized to placebo orally nightly&#xD;
Placebo: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>Group randomized to melatonin 3 mg orally nightly&#xD;
Melatonin: Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Group randomized to placebo orally nightly&#xD;
Placebo: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="1.2"/>
                    <measurement group_id="B2" value="14.1" spread="1.7"/>
                    <measurement group_id="B3" value="14.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Migraine/Migrainous Days Per 28 Day Period</title>
        <description>Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary.</description>
        <time_frame>final 4 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Group randomized to melatonin 3 mg orally nightly&#xD;
Melatonin: Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group randomized to placebo orally nightly&#xD;
Placebo: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Migraine/Migrainous Days Per 28 Day Period</title>
          <description>Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="4.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Minutes to Sleep Onset</title>
        <description>Number of minutes to sleep onset as measured by a FitBit.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Group randomized to melatonin 3 mg orally nightly&#xD;
Melatonin: Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group randomized to placebo orally nightly&#xD;
Placebo: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Minutes to Sleep Onset</title>
          <description>Number of minutes to sleep onset as measured by a FitBit.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="10.7"/>
                    <measurement group_id="O2" value="17.2" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Recruited From Each Recruitment Strategy</title>
        <description>Each recruitment strategy will be analyzed for number of participants successfully enrolled.</description>
        <time_frame>During the enrollment period, approximately 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All Participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Recruited From Each Recruitment Strategy</title>
          <description>Each recruitment strategy will be analyzed for number of participants successfully enrolled.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinic recruitment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Newspaper advertising</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Social media advertising (eg, Facebook and Google+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Electronic medical record letter invitation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence as Measured by Number of Openings Per Participant</title>
        <description>eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant.</description>
        <time_frame>during the &quot;At Home Active Study Period&quot; or Weeks 5-16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Group randomized to melatonin 3 mg orally nightly Melatonin: Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group randomized to placebo orally nightly Placebo: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence as Measured by Number of Openings Per Participant</title>
          <description>eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant.</description>
          <units>Mean Number of Openings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="27"/>
                    <measurement group_id="O2" value="60" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Diary Compliance Rate</title>
        <description>Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study.</description>
        <time_frame>Weeks 12-16 of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Group randomized to melatonin 3 mg orally nightly Melatonin: Taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group randomized to placebo orally nightly Placebo: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Diary Compliance Rate</title>
          <description>Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low iron on routine labs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Episode of vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Daytime tiredness</sub_title>
                <description>Daytime tiredness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Unscheduled medical visit for migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <description>1 kicked in the ribs&#xD;
1 kicked in the testicle&#xD;
1 passenger in a motor vehicle accident</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Gelfand, MD</name_or_title>
      <organization>UCSF Pediatric Headache Program</organization>
      <phone>415-885-7832</phone>
      <email>Amy.Gelfand@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

